The regulatory file for chymotrypsin
Chymotrypsin is an enzyme preparation, so the regulatory file has three anchors: where the material comes from, what the specification measures, and where the finished product will be sold. Origin shapes the species and TSE documents, the specification shapes the activity method and contaminant panel, and the destination shapes the route and label. The buyer's regulatory team confirms the route; this page maps the frameworks and the documents.
A chymotrypsin file is only as good as its source record and its method, and the destination market decides which route and label apply.
What the file contains
A file that can be reviewed answers four practical things. It names the material and the specification revision; it carries the certificate for the lot on the dock; it shows the limits and label rules that the destination applies to the finished product; and it records what happens when the source, the carrier or the particle size changes. The certificate covers the lot, the technical data sheet covers the specification and the safety data sheet covers handling. None of them answers the route question.
For an enzyme like this, three statements carry more weight than the rest: the species and tissue of origin, the TSE position when the material is pancreas-derived, and the identity of the carrier. A lactose carrier brings a milk allergen with it, so the allergen statement should name the carrier and not only the enzyme. If the material is fermentation-derived, the production organism and its construction replace the TSE question, and the file needs a different set of documents.
European Union
In the EU, Regulation (EC) No 1332/2008 is the food-enzyme framework, and it requires a food enzyme to be on the Union list before it can be placed on the market, whether it acts as an ingredient or as a processing aid. The list is still being completed; EFSA has published safety evaluations for chymotrypsin preparations, including one produced by a genetically modified Bacillus licheniformis strain. The buyer's regulatory team checks the current list and confirms that the preparation and the use are covered, as of this review.
Alongside it, Regulation (EC) No 999/2001 sets the TSE rules for animal material. Pancreas is not classified as specified risk material, but the regulation still asks for the species, the tissue and the country of origin, and those belong in the file. Regulation (EU) No 1169/2011 then decides whether the enzyme appears on the label: a processing aid that leaves no technological function in the finished food need not be declared, whereas an enzyme that stays in a supplement as an ingredient must be. Supplement labelling also depends on the member state.
United States
The US route depends on what the ingredient is doing. A food enzyme usually rests on a GRAS basis, which can come from a listing in 21 CFR Part 184, from a GRAS notice reviewed under 21 CFR Part 170, or from a self-affirmed conclusion supported by the supplier's evidence. A dietary supplement needs the dietary-ingredient framework, and a new dietary ingredient question looks at the marketing history before 15 October 1994. The buyer's regulatory team decides which basis applies to the finished product.
The panel, the other ingredients and the claim are reviewed separately. An activity figure on a certificate is not a permission, and a permitted ingredient does not turn an activity figure into a claim.
Contaminants and limits
The catalog limits apply to the powder as released. The file also needs the calculation at the daily dose, since a result that looks comfortable per kilogram can be close to the limit in a capsule. The table lists the panel and what the finished-product file should show.
| Parameter | Catalog limit | What the file should show |
|---|---|---|
| Lead (Pb) | ≤3 mg/kg | The lot figure, the method and the intake calculation |
| Arsenic (As) | ≤2 mg/kg | The lot figure and the destination limit |
| Cadmium (Cd) | ≤1 mg/kg | The lot figure and any category exception |
| Mercury (Hg) | ≤0.1 mg/kg | The lot figure and the method |
| Microbiology | APC ≤1,000 cfu/g; yeast and mould ≤100 cfu/g; E. coli and Salmonella absent | Counts, absence statements and the methods used |
| Loss on drying | ≤5.0% | The measured value, because water lowers activity per gram |
Claims and the label
No disease-related claim belongs on a chymotrypsin product, and enzyme activity is not a clinical effect. Any structure or function sentence is checked by the brand's reviewer against the market, the dosage form and the finished product; that check is independent of the certificate. A certificate describes a lot, not a label.
Two habits cause trouble. The first is to describe the enzyme by the protein it breaks down, which turns a technical property into a physiological claim. The second is to print “protease” on the panel when the specification names chymotrypsin, which loses the identity the rest of the file establishes. Use the enzyme name and the source, and leave the wording to the reviewer.
Great Britain and Northern Ireland follow separate routes. The GB file is checked against the GB register and GB labelling rules; Northern Ireland stays inside the EU framework. The buyer keeps the evidence for whichever route the destination requires.
Documents in the file
| Document | What it establishes | Ask for it when |
|---|---|---|
| Specification | Revision, activity, method and limits | Before accepting the quotation |
| COA | Results for the lot that ships | With every lot |
| Technical data sheet | Form, solubility, storage and packaging | During supplier qualification |
| Safety data sheet | Dust, sensitisation and safe handling | Qualification and warehouse use |
| Source and TSE statement | Species, tissue, country and TSE position | Before the first shipment |
| Allergen and carrier statement | Carrier identity and allergen risk | Before the label is designed |
| GMO and origin statement | Production organism and manufacturing site | At qualification |
| Residual solvent statement | Solvents used in purification | Where the market requires it |
Checklist before the first order
- The specification identifies the enzyme, its source, CAS 9004-07-3 and the ATEE method.
- Versioned copies of the COA, TDS and SDS are in the file.
- Source, TSE position and carrier are all confirmed in writing.
- The metals results have been recalculated for the daily dose.
- A destination review covers both the label text and the claim.
- Change control extends to source, carrier and particle size.
The catalog entry is on the chymotrypsin product page; the COA page explains the lot certificate, the identity page covers the analytical evidence, while the EU and US regulatory notes give the framework references. Release handling is described on the quality page.
Related documents
Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.
Request a quotation